Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Mahal on the Prevalence of Prostate Cancer in African American Men

November 2nd 2020

Brandon Mahal, MD, assistant professor of radiation oncology, assistant director of community outreach and engagement, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the prevalence of prostate cancer among African American men.

FDA Lifts Hold on Phase 1 Trial of CAR T-Cell Therapy P-PSMA-101 in mCRPC

November 2nd 2020

The FDA has lifted the clinical hold placed on the phase 1 PSMA-101-001 study of the CAR T-cell therapy P-PSMA-101 in patients with metastatic castration-resistant prostate cancer.

Dr. Shore on the Need for Further Education on Molecular Testing in mCRPC

October 29th 2020

Neal D. Shore, MD, FACS, discusses the need for further education on molecular testing for metastatic castration-resistant prostate cancer.

Treatment Based on Advanced Molecular Imaging Can Improve DFS in Prostate Cancer

October 28th 2020

The use of advanced molecular imaging with the PET radiotracer fluciclovine (18F) to inform treatment decisions can lead to improved disease-free survival rates in patients with recurrent prostate cancer.

Dr. Theurillat on Castration and AR Inhibition in Prostate Cancer

October 27th 2020

Jean-Philippe Theurillat, MD, discusses castration and androgen receptor inhibition in prostate cancer.

Dr. Lin on the Role of Genomic Markers in Prostate Cancer

October 27th 2020

Daniel W. Lin, MD, discusses the role of genomic markers in prostate cancer.

Dr. Abdulkadir on the Rationale to Target MYC in Prostate Cancer

October 27th 2020

Sarki A. Abdulkadir, MD, PhD, discusses the rationale to target MYC in prostate cancer.

Enzalutamide Plus ADT Improves rPFS in Metastatic Hormone-Sensitive Prostate Cancer, Regardless of Baseline PSA Levels

October 27th 2020

The addition of enzalutamide to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer improved radiographic progression-free survival, regardless of baseline prostate-specific antigen levels.

Dr. Boutros on Processes That Predict Lethality in Prostate Cancer

October 26th 2020

Paul C. Boutros, PhD, MBA, discusses processes that predict disease lethality in men with prostate cancer.

Dr. Mahal on the Potential Role of Race in Prostate Cancer Disparities

October 23rd 2020

Brandon Mahal, MD, discusses the potential role of race with regard to molecular disparities among men with prostate cancer.

Dr. Baskin on Treatment Considerations in Prostate Cancer

October 23rd 2020

Monica L. Baskin, PhD, discusses treatment considerations in prostate cancer.

Dr. Azad on the Significance of the PROfound Trial in mCRPC

October 23rd 2020

Arun Azad, PhD, discusses the significance of the PROfound trial in metastatic castration-resistant prostate cancer.

Dr. Kantoff on Future Research Efforts in Prostate Cancer

October 23rd 2020

Philip W. Kantoff, MD, discusses future research efforts in prostate cancer.

Dr. Shore on Unmet Needs in Nonmetastatic CRPC

October 23rd 2020

Neal D. Shore, MD, FACS, discusses unmet needs in nonmetastatic castration-resistant prostate cancer.

Dr. Petrylak on Future Research in Prostate Cancer

October 22nd 2020

Daniel P. Petrylak, MD, discusses future research in prostate cancer.

Alternative Surgical Technique Induces Early Return of Continence in Localized Prostate Cancer

October 22nd 2020

A novel surgical technique called the “hood technique” for robotic-assisted radical prostatectomy was shown to achieve early return of urinary continence without a negative impact on complications and cancer outcomes among men with localized prostate cancer.

Dr. McDermott on Preventing Recurrence of High-Risk Prostate Cancer

October 21st 2020

Ray McDermott, discusses preventing recurrence in patients with very high-risk prostate cancer.

Dr. Hussain on Meaningful Effect as an End Point in Prostate Cancer Trials

October 21st 2020

Maha Hussain, MD, FACP, FASCO, discusses the importance of meaningful effect in prostate cancer trials.

Darolutamide/ADT Continues to Demonstrate Favorable Tolerability in Nonmetastatic CRPC

October 21st 2020

Neal D. Shore, MD, FACS, highlights the role of darolutamide plus androgen deprivation therapy and how it continues to demonstrate a highly favorable tolerability and safety profile in patients with nonmetastatic castration-resistant prostate cancer.

Onvansertib Combo Achieves Disease Control, Overcomes Abiraterone Resistance in mCRPC

October 20th 2020

The combination of onvansertib plus abiraterone acetate and prednisone achieved disease control in patients with metastatic castration-resistant prostate cancer who had initial resistance to abiraterone.